Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.

Anis A HamidKaspar WillsonAndrew D VincentBabak TamjidMargaret LeeAlice BerginChun GanAinsley CampbellJosephine StewartCarmel PezaroBen TranAndrew J Weickhardt

Published in: Asia-Pacific journal of clinical oncology (2018)

LD docetaxel for mCRPC did not mitigate the risk of FN or ETC due to toxicity. Dose reduction may result in poorer PSA response and survival.

Keyphrases

prostate cancer
squamous cell carcinoma
locally advanced
small cell lung cancer
chemotherapy induced
oxidative stress
radiation therapy
middle aged
combination therapy
radical prostatectomy
urinary tract infection
free survival
rectal cancer
replacement therapy
smoking cessation